PERNIX
THERAPEUTICS HOLDINGS, INC.
|
(Exact name of registrant as specified in its charter) |
Maryland
|
001-14494
|
33-0724736
|
||
(State
or other jurisdiction
of
incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
33219
Forest West Street Magnolia,
TX
|
77354
|
|
(Address
of principal executive offices)
|
(Zip
Code)
|
o
|
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
2.1
|
Asset
Purchase Agreement dated January 8, 2010 by and between Sciele Pharma,
Inc. as Seller and Pernix Therapeutics, Inc. as Buyer1
|
99.1 | Press release issued by the Company on March 24, 2010. |
PERNIX THERAPEUTICS HOLDINGS, INC. | |||
Dated: March 30,
2010
|
By:
|
/s/ Cooper Collins | |
Cooper Collins | |||
President and Chief Executive Officer | |||
Exhibit
No.
|
Description
|
2.1
|
Asset
Purchase Agreement dated January 8, 2010 by and between Sciele Pharma,
Inc. as Seller and Pernix Therapeutics, Inc. as Buyer
|
99.1
|
Press
Release of Pernix Therapeutics Holdings, Inc. dated March 24,
2010
|